c-Met inhibitors

被引:18
|
作者
Mughal, Anum [1 ]
Aslam, Hafiz Muhammad [1 ]
Sheikh, Asfandyar [1 ,2 ]
Khan, Agha Muhammad Hammad [3 ]
Saleem, Shafaq [1 ]
机构
[1] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[2] Pakistan Res Evolut Students Soc, Karachi, Pakistan
[3] Dow Univ Hlth Sci, Sindh Med Coll, Karachi, Pakistan
来源
关键词
c-Met; Tyrosine kinase; Cancer; HEPATOCYTE GROWTH-FACTOR; FACTOR-RECEPTOR; SOMATIC MUTATIONS; KINASE INHIBITORS; ONCOGENE; IDENTIFICATION; PROTOONCOGENE; DISCOVERY; DOMAIN; GENE;
D O I
10.1186/1750-9378-8-13
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio-or immunotherapy
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Have Clinical Trials Properly Assessed c-Met Inhibitors?
    Hughes, Veronica S.
    Siemann, Dietmar W.
    TRENDS IN CANCER, 2018, 4 (02): : 94 - 97
  • [32] Design, synthesis, and biological evaluation of potent c-Met inhibitors
    D'Angelo, Noel D.
    Bellon, Steven F.
    Booker, Shon K.
    Cheng, Yuan
    Coxon, Angela
    Dominguez, Celia
    Fellows, Ingrid
    Hoffman, Douglas
    Hungate, Randall
    Kaplan-Lefko, Paula
    Lee, Matthew R.
    Li, Chun
    Liu, Longbin
    Rainbeau, Elizabeth
    Reider, Paul J.
    Rex, Karen
    Siegmund, Aaron
    Sun, Yaxiong
    Tasker, Andrew S.
    Xi, Ning
    Xu, Shimin
    Yang, Yajing
    Zhang, Yihong
    Burgess, Teresa L.
    Dussault, Isabelle
    Kim, Tae-Seong
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) : 5766 - 5779
  • [33] Triazolopyridazine derivatives as selective and orally bioavailable c-Met inhibitors
    Romero, Karina
    Bauer, David
    Bellon, Steve
    Berry, Loren M.
    Bode, Christiane
    Boezio, Alessandro
    Broome, Martin
    Choquette, Deborah
    Chen, April
    Dussault, Isabelle
    Huang, Liyue
    Kaplan-Lefko, Paula
    Lewis, Richard
    Lin, Jasmine
    Lohman, Julia
    Potashman, Michele
    Rex, Karen
    Shah, Kavitah
    Shimanovich, Roman
    Teffera, Yohannes
    Yang, Yajing
    Zhang, Michael
    Zhao, Zhiyang
    Harmange, Jean-Claude
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [34] Discovery of c-Met kinase inhibitors for anticancer therapeutics.
    Yun, Chang-Soo
    Cho, Sung Yun
    Kim, Hyoung Rae
    Jung, Hee Jung
    Ha, Jae D.
    Lee, Kwangho
    Kim, Pilho
    Park, Chi Hoon
    Lee, Chong Ock
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [35] Identification of orally active small molecule c-met inhibitors
    Miknyoczki, Sheila
    Underiner, Ted
    Aimone, Lisa
    Chang, Hong
    Galinis, Debbie
    Grobelny, Jennifer
    Hebertz, Torsten
    Huang, Zeqi
    Husten, Jean
    Mikiewicz, Karen
    Murthy, Seetha
    Pritchard, Sonya
    Weinberg, Linda
    Worrell, Candace
    Ator, Mark
    Dorsey, Bruce
    Ruggeri, Bruce
    CANCER RESEARCH, 2009, 69
  • [36] Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase
    Porter, John
    Lumb, Simon
    Lecomte, Fabien
    Reuberson, James
    Foley, Anne
    Calmiano, Mark
    le Riche, Kelly
    Edwards, Helen
    Delgado, Jean
    Franklin, Richard J.
    Gascon-Simorte, Jose M.
    Maloney, Alison
    Meier, Christoph
    Batchelor, Mark
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (02) : 397 - 400
  • [37] Prevalence of c-Met overexpression (c-Met plus ) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC
    Motwani, M.
    Panchabhai, S.
    Bar, J.
    Girard, N.
    Bradbury, P.
    Lu, S.
    Jin, J.
    Hotson, A.
    Maag, D.
    Planchard, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1169 - S1170
  • [38] Anticancer effects of c-Met inhibitors in esophageal squamous cell carcinoma
    Tzao, Ching
    Wang, Chun-Ya
    Lee, Meng-Ching
    Chen, Ban-Hen
    Sun, Guang-Huan
    CANCER RESEARCH, 2012, 72
  • [39] c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
    Christensen, JG
    Burrows, J
    Salgia, R
    CANCER LETTERS, 2005, 225 (01) : 1 - 26
  • [40] Recent advances in the discovery of small molecule c-Met Kinase inhibitors
    Parikh, Palak K.
    Ghate, Manjunath D.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 143 : 1103 - 1138